FT News Briefing Analysis: US Yen-Buying Intervention—Novo Nordisk's M&A Strategy and Russia's LNG Shadow Fleet (August 4, 2026)

Overview

In this episode of the FT News Briefing, we cover three international topics: M&A in the pharmaceutical industry, Russian sanctions evasion tactics, and a historic currency intervention. First, we report on the Novo Nordisk CEO's appetite for large-scale acquisitions and the industry restructuring facing patent cliffs. Next, we delve into the reality of Russia organizing a 'shadow fleet' of used tankers to continue gas exports ahead of the EU's ban on Russian LNG imports. Finally, we explain the details behind the unusual move by the US to coordinate with Japan on yen-buying intervention, including its objectives and the market's skeptical view.

AstraZeneca shares fall on speculation of major merger with BMS

AstraZeneca's share price fell on Monday following a scoop by the Financial Times (FT) on Sunday regarding a potential large-scale merger between the British pharmaceutical giant and US drugmaker Bristol Myers Squibb (BMS). This was due to growing concerns among investors regarding the feasibility of this mega-deal and its ultimate transaction value.

Multiple risks have been pointed out regarding this merger, including antitrust hurdles and the final valuation of the deal. However, regardless of the success or failure of this specific case, the trend of M&A in the pharmaceutical industry is not expected to stop. For drug manufacturers facing patent expirations, integration with other companies and the acquisition of promising development pipelines remain the most critical management challenges.

Novo Nordisk CEO eager for acquisitions of all sizes

Aaron Kirchfeld, European Business Correspondent for the Financial Times (FT), conducted an exclusive interview with Mike Duestar, CEO of Danish pharmaceutical giant Novo Nordisk, at the company's headquarters. Duestar stated clearly that large-scale mergers and acquisitions (M&A) are 'not outside the realm of possibility' for the company, showing a positive stance toward deals of all sizes.

As a specific example, he mentioned the fact that the company had bid for Metsera in a deal worth $10 billion (approximately 1.57 trillion yen at an exchange rate of 157.16 yen to the dollar), stating, 'In my eyes, that doesn't even look like a large-scale deal,' and emphasized that he is open to even larger and more transformative transactions. For Duestar, the essence of an acquisition is not the scale, but whether it can complement and expand the company's development pipeline.

Behind this is the 'patent cliff' problem facing the entire pharmaceutical industry. This is the risk that revenue will drop sharply as patents for flagship drugs expire, allowing generic drugs to enter the market. For this reason, major pharmaceutical companies are acquiring promising treatments from biotechnology firms, and there is also an increase in mega-mergers spanning the Atlantic, such as the one between AstraZeneca and Bristol Myers Squibb reported by the FT over the weekend.

About a year has passed since Duestar took office. Hired to drive change and stabilize management, he made the tough decision to cut 9,000 jobs shortly after taking office, one of the largest in Danish history. He also revamped the board of directors and lowered earnings guidance. Novo Nordisk has grown into the company with the largest market capitalization in Europe as a pioneer in obesity treatments, but it has since faced intense competition from US-based Eli Lilly and generic drug manufacturers.

Duestar's greatest achievement amidst these headwinds is the successful launch of the oral obesity treatment 'Wegovy tablets.' As of June, the number of prescriptions in the US reached 3 million, making it one of the most successful new drug launches in US pharmaceutical history. Even after competitor Eli Lilly brought a rival drug to market, sales have continued to accelerate.

Novo Nordisk is scheduled to announce its financial results tomorrow (August 5, 2026), and an update on the sales progress of Wegovy tablets is expected. On the other hand, the company's 2026 revenue and operating profit are expected to decrease by up to 12%. It is believed that it will take more time for the effects of the cost-cutting and acquisition measures pushed by Duestar to appear. He uses the expression 'shoot on goal,' explaining that increasing the number of attempts without fear of failure is the path to success.

However, Kirchfeld points out that investors are demanding a clearer path for the company to break away from its dependence on diabetes and obesity-related drugs, and the focus will be on how patient they can be with this trial-and-error strategy. That said, he is the company's first foreign CEO, and the fact that the conservative Novo Nordisk selected him is in itself a sign of a strong will for change. Therefore, the board of directors is expected to give him a certain amount of time. However, it cannot be denied that if concrete results are not seen, the patience of investors may run out.

Russia organizes 'shadow fleet' to continue LNG exports

The FT reports that Russia is quietly preparing a 'shadow fleet' to circumvent sanctions before the European Union (EU) implements a total ban on imports of Russian liquefied natural gas (LNG) starting in 2027. Russia has already been using a so-called 'dark fleet' to dodge Western sanctions on oil exports, and this move is the LNG version of that.

EU countries are still large buyers of Russian gas, and in the first half of this year, they purchased almost the entire production of the Yamal LNG plant in Siberia. However, the EU is moving to ban imports to cut off fossil fuel revenue that is funding the war in Ukraine. This shadow LNG fleet consists of used tankers and vessels built within Russia, many of which are owned by Russian shell companies based in Dubai, Hong Kong, Singapore, etc., and operated as flags of convenience.

These tankers are believed to use tactics such as jamming Automatic Identification System (AIS) signals or conducting ship-to-ship transfers on the high seas to disguise the origin of their cargo.

US coordinates intervention with Japan, an unusual structure for supporting the yen

As Japan faces a historic depreciation of the yen, an extremely unusual situation has occurred where the US has directly stepped into currency intervention. Katie Martin, an FT markets columnist and host of the podcast 'Unhedged,' explained the background of this move.

Last week, the yen fell to its lowest level against the dollar in about 40 years, with some moments seeing it hit the 164 yen range. For Japan, which had seen limited effectiveness from repeated solo interventions, the US stepped up from verbal support over the past few months to direct intervention by the Treasury Department last Friday. Japan's Ministry of Finance also confirmed this week that it had carried out this historic coordinated intervention with the US Treasury. Furthermore, US officials have stated that they are prepared to take similar action again if necessary. Following this coordinated intervention, the rate has recovered to the 155 yen range.

According to Martin, it is extremely rare for the US to intervene to support another country's currency. Precedents include the G7 coordinated effort to curb the yen's appreciation following the 2011 Great East Japan Earthquake, and the support for the Argentine peso prior to the election in Argentina the previous year. However, the Argentine peso is a very small currency. This is the first time in about 30 years that yen-buying intervention has been carried out on this scale, and Martin points out that 'these things are really, really rare.'

The background to the US taking this action is analyzed as having two main objectives. The first is geopolitical, serving as a performance to demonstrate solidarity with an ally. The second is the more practical stabilization of financial markets. For Japan to defend the yen on its own, it would require either a sharp interest rate hike or a large-scale sale of its holdings of US dollars (i.e., US Treasuries). The latter, in particular, could deal a further blow to an already weak US Treasury market. By stepping in for a joint intervention, the US is seen as intending to send a strong signal to yen sellers to 'take us on,' thereby checking speculative selling.

Another point of interest is how this intervention was funded. The US sold its holdings of euros, not dollars, to purchase yen. This was due to the US wanting to avoid a situation where it would have to conduct large-scale dollar or US Treasury sales itself, as well as the technical reality that the majority of the Exchange Stabilization Fund was already composed of euros and yen. The European Central Bank (ECB) was notified in advance, so it did not come as a surprise to them.

However, there are persistent voices in the market questioning the effectiveness of this coordinated intervention. The view is that unless Japan commits to large-scale interest rate hikes or a major shift in its fiscal structure, the fundamental trend of a weak yen will not change. Martin points out that the true aim of the intervention may have been to intimidate the market and achieve 'big results with small intervention.'

▶ Previous entry in this series: FT News Briefing Analysis: Amazon Earnings, FIFA's Commercialization Plan, JPMorgan's AI Hedge Fund Collapse, and Congo's Radioactive Material Issue (July 31, 2026) https://note.com/yondo/n/n0c69182d43ec

▶ Read articles on this theme: Magazine 'US Stocks and Market Issues' https://note.com/yondo/m/mb4ec8df94ddb

#Europe #EconomicNews #FT #AstraZeneca #BristolMyersSquibb #NovoNordisk #EliLilly #M&A #Pharmaceuticals #ObesityDrugs #Restructuring #Earnings #YenBuyingIntervention #CurrencyIntervention #USTreasuries #TreasuryDepartment #Russia #LNG #SanctionEvasion #ShadowFleet